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Increasing evidence suggests that-synuclein (S) aggregates
in brains of individuals with Parkinson’s disease and dementia
with Lewy bodies can spread in a prion-like manner. Although
the initial S nuclei are pivotal in determining S fibril poly-
morphs and resulting phenotypes, it is not clear how the initial
fibril seeds are generated. Previous studies have shown that S
truncation might have an important role in S aggregation.
However, little is known about how this truncation influences
S’s propagation properties. In the present study, we generated
S fibrils from a series of truncated humanS constructs, char-
acterized their structures and conformational stabilities, and
investigated their ability to convert the conformation of full-
length S in vitro, in cultured cells, and in WT mice. We show
that both C- and N-terminal truncations of human S induce
fibril polymorphs and exhibit different cross-seeding activities.
N-terminally 10- or 30-residue–truncated human S fibrils
induced more abundant S pathologies than WT fibrils in
mice, whereas other truncated fibrils induced less abundant
pathologies. Biochemical analyses of these truncated fibrils
revealed that N-terminal 10- or 30-residue truncations of
human S change the fibril conformation in a manner that
increases their structural compatibility with WT mouse S
fibrils and reduces their stability. C-terminally 20-residue–
truncated fibrils displayed enhanced seeding activity in vitro.
Our findings imply that truncation of S can influence its
prion-like pathogenicity, resulting in phenotypic diversity of
-synucleinopathies.
Misfolding and aggregation of normally soluble proteins are
common pathological features of many neurodegenerative dis-
eases (1). -Synucleinopathies, including Parkinson’s disease
(PD)3, dementia with Lewy bodies (DLB), and multiple system
atrophy (MSA) are associated with formation of abnormal
aggregates of-synuclein (S), a natively unfolded 14-kDa pro-
tein consisting of 140 amino acids. These diseases are neuro-
pathologically characterized by the deposition of filamentous
S aggregates with cross- structure (2), which are abnormally
phosphorylated (3) and partially ubiquitinated (4). S and var-
ious other neurodegenerative disease–related proteins, includ-
ing -amyloid (A), tau, and TAR-DNA–binding protein-43
(TDP-43), can propagate through neural networks in a similar
manner to abnormal prion proteins in prion diseases, in which
abnormal insoluble protein acts as a seed or template for con-
verting soluble protein to abnormal form (5, 6). Although in
vitro (7, 8) and in vivo (9–11) experiments using detergent-
insoluble fraction of diseased brains and aggregated recombi-
nant proteins as seeds have provided support for the “prion-like
propagation hypothesis,” it is not yet clear how S aggregates
propagate through the diseased brain.
In MSA, S is mainly deposited in glial cells, whereas S
aggregates are found in neuronal cells in PD and dementia with
Lewy bodies (DLB) (12). Such phenotypic differences suggest
the existence of different “strains” of pathogenic S, whose
aggregate structures determine clinical phenotypes, as in prion
diseases (13, 14). Although the differences in cross-seeding
activity between MSA and PD brain extracts in heterozygous
mice transgenic for A53T human S suggest that structural
differences exist (11, 15), the mechanisms that cause such
structural variations among sporadic -synucleinopathies
remain unclear.
In Lewy bodies, not only full-length (FL), but also truncated
S is accumulated (16). Truncation is a common posttransla-
tionalmodification that is not specific to the diseased brain, and
about 15% of S is truncated even in the brain of healthy indi-
viduals (17). In the diseased brain, bothN-terminally andC-ter-
minally truncated S species are present (18). Overexpression
of truncated S or coexistence of truncated and FL S can
enhance aggregation and neurodegeneration both in vitro (19,
20) and in vivo (21, 22). Although it has been suggested that
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truncation has an important influence on S aggregation (19,
23, 24), very few studies have focused on the effect of truncation
on prion-like propagation.
In the present study,we systematically investigated the struc-
tural polymorphism of truncated S fibrils and examined
whether or not these fibrils can act as templates for FLS aggre-
gation, using in vitro and in vivo experimental models. We
found that differently truncated human S fibrils exhibit a variety
of cross-seeding activities in vitro and in vivo. Our results imply
that truncationofS in the initial nucleationphasemight not only
influence aggregation, but also result in phenotypic diversity.
Results
Fibril formation from truncatedS proteins
To investigate the effects of C- and N-terminal truncations
on S aggregation, we prepared a series of wildtype (WT) and
truncated human S (Fig. 1A). The constructs were expressed
in Escherichia coli, and the purified soluble S proteins were
analyzed by SDS-PAGE (Fig. 1B). After agitation in the pres-
ence of 150 mM KCl, the formation of fibrillar aggregates
was confirmed by negative-staining transmission electron
microscopy (TEM) (Fig. 1C). The fibrils were 6–10 nm in
Figure 1. HumanWT and truncatedS fibril seeds. A, schematic representation of the humanWT and truncated S variants used in this study. The shaded
portion indicates the reported core region (residues 31–109) ofWTS fibrils. B, CBB staining of purifiedS proteins.C, negative staining TEM images ofWT and
truncated S fibrils. Scale bars, 100 nm. D, aggregation kinetics of human FL Smonomers under quiescent conditions in the absence or presence of 1 mol %
human WT or truncated S fibril seeds, monitored by ThT fluorescence. Curves are averages of three samples. The S concentration was 150 M in all
experiments.
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diameter and did not branch. In agreement with a previous
report (25), human C-terminally truncated S fibrils (C20
and C30) tended to be shorter than WT fibrils and were
bundled laterally, whereas human N-terminally truncated
S formed long fibrils similar toWT fibrils (26). These fibrils
bound to thioflavin T (ThT), which is commonly used to
detect amyloid formation, and showed enhanced fluores-
cence (Fig. S1).
To examine whether these truncated S fibrils could act as
seeds for FL S aggregation, seeding assay against human
WT S monomer was performed by incubation under qui-
escent conditions in the presence or absence of 1 mol % of
preformed human S fibril seeds in vitro (Fig. 1D). WT and
all truncated S fibrils induced the aggregation of FL S
protein, but the ThT fluorescence was not increased in the
absence of S fibril seeds. We found that C20 seeds drasti-
cally increased the rate of fibril assembly (t1⁄2  2  0 h),
compared with WT seeds (t1⁄2  26  6 h). N10 seeds and
N30 also induced fibril assembly, but more slowly (t1⁄2 
76  3 and 58  1 h, respectively).
Effect of truncation on induction of phospho-S pathology in
WTmice
To examine the cross-seeding activity of human truncated
S fibril seeds inWTmouse brain,we injected 750 pmol human
WT and truncated S fibril seeds into the right striatum ofWT
mice. Three months after injection, paraffin-embedded brain
sections were prepared and immunostained with anti–phos-
pho-S antibody (pSer-129/EP1536Y) (Fig. 2,A and B). Inmice
injected with WT seeds, Lewy body/Lewy neurite-like phos-
pho-S aggregates were distributed bilaterally through the
brain, including striatum (Str), substantia nigra (SN), amygdala
(Amy), and anterior cingulate cortex (ACC). Only sparse
phospho-S–positive structures were observed in mice in-
jected with C10 seeds, C20 seeds, and C30 seeds, and
these were restricted to Str, SN, and Amy in the injected hemi-
sphere. On the contrary, abundant phospho-S aggregates
were observed throughout the bilateral brain, including Str, SN,
Amy, and ACC, in mice injected with N10 seeds and N30
seeds. To evaluate the accumulated S biochemically, we ana-
lyzed sarkosyl-insoluble fractions (Sar-ppt) from whole mouse
brain (Fig. 2C). The amounts of insoluble phospho-S in mice
injected with N10 seeds and N30 seeds were larger than in
mice injected with WT seeds, whereas only very faint bands
were detected in mice injected with C10 seeds, C20 seeds,
C30 seeds, and N20 seeds (Fig. 2D). These phospho-S
bands were stained with anti-mouse S-specific antibody
(D37A6), but not with anti-human S-specific antibody
(LB509). We also compared the amount of insoluble mouse S
but did not find any difference among the mice because of the
high basal signal detected in mock-treated mice. These results
indicate thatN-terminal 10- or 30-residue truncation of human
S enhances the cross-seeding activity with WT mouse S in
vivo, despite the low seeding activity in vitro (Fig. 1D). On the
other hand, the cross-seeding activities are reduced by C-ter-
minal truncations and N-terminal 20-residue truncation.
Effect of truncation on seed-dependent aggregation ofS in
cultured cells
To further confirm these differences,we compared the cross-
seeding activities using a cultured cell model. SH-SY5Y cells
transiently expressing mouse WT S were transfected with
humanWT and truncated S fibril seeds: C20, N10, N20,
and N30 seeds. Two days after transfection, we checked the
presence of insolubleS aggregates in cells by biochemical frac-
tionation and Western blot analysis (Fig. 3A). The levels of
mouse S in sarkosyl-insoluble fraction were increased in
cells treated with S fibril seeds, and the insoluble mouse S
bands were positive to anti–phospho-S antibody (pSer-129/
pSyn#64). The amount of insoluble phosphorylated S in cells
treated with N30 seeds was larger than those in cells treated
withWTseeds, whereas the amounts in cells treatedwithN20
seeds and C20 seeds were relatively small (Fig. 3B). We also
compared the amount of insoluble mouse S and found the
amount of insoluble mouse S in cells treated with N30 seeds
was larger than those in cells treated with WT seeds. Similar
results were observed when SH-SY5Y cells overexpressing
FLAG-human S were treated with truncated fibril seeds (Fig.
S2). These results indicate that human truncated S fibrils can
convert soluble mouse and human FL S into insoluble form,
and some N-terminal truncations have more potent cross-
seeding activities in cultured cells.
Truncation induces fibril polymorphs ofS
As described above, N-terminal 10- or 30-residue truncation
of human S results in increased cross-seeding activity in vivo,
suggesting that these truncations induce different fibrillar poly-
morphs. In this context, the protease digestion pattern reflect
the structure of the cross- sheet–rich fibril core region, and is
commonly used to characterize the conformations of amyloid
fibrils (27–29). Therefore, we compared the proteinase K (PK)–
resistant fractions of truncated human S fibrils with those of
WT mouse S fibrils. WT mouse S fibrils (WTMo seed)
showed10 and8 kDa PK-resistant fractions after PK diges-
tion, whereas WT human S fibrils (WTHu seed) yielded 12
and 8 kDa fractions (Fig. 4A). The N-terminally truncated
human S fibrils showed a WT mouse-like digestion pattern,
suggesting that these fibrils share a common fibril core struc-
ture with WT mouse fibrils. In contrast, the C20 fibrils
showed a WT human-like digestion pattern. Next, we com-
pared the digestion patterns of FL mouse S aggregates
(FLAMo) seeded with the S fibrils. FL mouse S aggregates
obtained with WTMo seed (FLAMo–WTMo) showed 10 and
8 kDa resistant fractions after PK digestion, whereas aggre-
gates withWTHu seed (FLAMo–WTHu) were digested into low-
molecular fractions (Fig. 4B). FLmouse S aggregates obtained
with N-terminal truncated fibril seeds (FLAMo–N10, –N20,
and –N30) showed FLAMo–WTMo–like digestion patterns,
whereas FLAMo–C20 showed a FLAMo–WTHu–like pattern.
These results imply that the N-terminal truncations of human
S have similar conformations toWTmouseS fibrils, and can
work as seeds for mouse S monomer to form S fibrils with
structural properties similar to those of WT mouse S fibrils.
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N-terminal 10- and 30-residue–truncated humanS fibrils
have decreased conformational stability
As described above, theN-terminal truncations of humanS
form mouse S–like fibrils, but sequential N-terminal trunca-
tions show biphasic seeding effects in mouse brain: Fibrils of
N10 and N30 have greater effects than fibrils of N20 (Fig.
2). In the prion field, there is a general consensus that seeding
capacity is inversely related to fibril stability (30). Here, we
examined the stability of the fibrils by treating WT and N-ter-
minally truncated humanS fibrils with a chemical denaturant,
Figure 2. Comparison ofS pathologies inWTmouse brains by inoculation of humanWTand truncatedS fibril seeds. A, distributions of phospho-S
pathology inWTmousebrains.WTmice injectedwith humanS fibrils into the striatumwere assessed at 3months after injection.Spathologywas evaluated
by immunohistochemistry with anti–pSer-129 antibody (EP1536Y). Sections were counterstained with hematoxylin. Representative images of ipsilateral
striatum (Str), substantia nigra (SN), amygdala (Amy), and anterior cingulate cortex (ACC) of inoculatedmice are shown. Scale bars, 25m. B, quantification of
phospho-S pathology of each area (red, injection side; blue, contralateral side). Data are shown as mean percentage area occupied by pSer-129–positive
structures  S.E. (n  3 per group). N.D., not detected. *, p  0.05; **, p  0.01; ***, p  0.001. C, Western blot analysis of sarkosyl-soluble (sup) and
sarkosyl-insoluble (ppt) fractions of injected brain extracts. The blots were probed using anti-pSer-129 (pSyn#64), anti-mouseS specific (D37A6), anti-human
S specific (LB509), and anti-tubulin  antibodies. LB509, which recognizes 115–122 of human S, cannot bind C20 and C30. Data are representative of
three independent experiments.D, quantification of relative insoluble phospho-S (upper) andmouse-S (lower). Data presented are themeans S.E. (n 3
per group). ***, p 0.001.
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sarkosyl, and separating the products into supernatant and pel-
let fractions by ultracentrifugation (Fig. 5). In the case of WT
human S,36% of the total protein was fractionated into the
pellet (36  4% of total protein). The N10 and N30 fibrils,
which could propagate efficiently in mouse brain, showed
decreased conformational stability (15  5% and 19  6% of
total protein in the pellet, respectively). On the other hand, the
N20 fibrils, which exhibited inefficient seeding in vivo,
showed increased stability (58 3% of total protein in the pel-
let). These results indicate that N-terminal 10- or 30-residue
truncation enhances the cross-seeding activity in vivo as a result
of decreased stability, implying that S fibrils are propagated
through a prion-like molecular mechanism.
C-terminal 20-residue truncation induces distinctive prion-like
properties
Although C20 fibrils showed drastically enhanced seeding
activity in vitro, they induced only sparse S pathology in vivo
(Figs. 1D and 2). To investigate whether the apparent inconsis-
tency is because of their structural characteristics, we analyzed
the structures of the seeded FL S aggregates (FLA)–C20 in
vitro and in cultured cells. TEM images showed that FLA
seeded with C20 seeds (FLA–C20) had a twisted morphol-
ogy that differed from the others, which showed straight,
unbranched fibrillar structures with a diameter of10 nm (Fig.
6A; Fig. S3A). To explore the difference of the underlying struc-
tures, we quantified the ThT-binding properties of the seeded
FL S aggregates. FLA-C20 showed higher binding affinity
(211  8% of FLA–WT) (Fig. S3B). The rate of FL WT S
aggregation in the presence of FLA–C20 was faster (t1⁄2 5
0 h) than that of FLA–WTHu (t1⁄2 28 2 h) (Fig. 6B). We also
examined the seeding activities of the FL S aggregates in cul-
tured cells. FLA–C20 showed poor seeding activity in cul-
Figure 4. Concentration-dependent proteinase K digestion assays ofS
aggregates. S fibrils were treatedwith PK (0, 1, 10, 100g/ml) for 30min at
37 °C. After treatment, the samples were resolved using SDS-PAGE and
stained by CBB. A, FL and truncated human S fibril seeds. B, FL mouse S
aggregates seededwithmouseWTS fibril seeds (WTMo), humanWTS fibril
seeds (WTHu), and human truncatedS fibril seeds. A filled circle indicates the
band at12 kDa; a filled arrowhead indicates the band at10 kDa; an open
arrowhead indicates the band at 8 kDa. Three independent experiments
were done and representative data are shown.
Figure 3. Cross-seeding activity of humanWTand truncatedS fibrils in cultured cells. SH-SY5Y cells expressingWTmouse-Swere transfectedwith the
S fibril seeds. After 2 days, cells were collected, lysed with A68 buffer containing 1% sarkosyl, and fractionated. The supernatant (sup) and the pellet (ppt)
fractions were subjected toWestern blot analysis. A, Western blot analysis using anti-pSer-129 (pSyn#64), anti-mouseS (D37A6), and anti-tubulin antibod-
ies. B, quantification of relative insoluble phospho-S (upper) and mouse-S (lower). Data presented are the means S.E. (n 3 per group). *, p 0.05.
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tured cells (Fig. 6, C and D). These results indicate that C20
fibrils induce distinct structures of FL S aggregates and these
aggregates have similar but different seeding properties with
C20 fibrils in vitro and in cells (Figs. 1 and 3).
Discussion
Aggregation of S can be influenced by mutations of SNCA
gene (31–38), phosphorylation (39), and various other external
conditions, including salt concentration (40, 41) and pH (42),
during in vitro assembly. HumanS can be cleaved either at the
N or C terminus by calpain 1 (16), plasmin (43), neurosin (44),
20S proteasome (19, 23), cathepsin D (45), caspase-1 (46),
matrixmetalloproteinase-3 (47), and asparagine endopeptidase
(48), resulting in the production of a range of aggregation-
prone truncated species (20, 49, 50). Our results show that
C-terminal and N-terminal truncations not involved in the
reported human S fibril core region (residues 31–109) (28)
induced fibril polymorphism characterized by different in vitro
and in vivo propagation properties (Fig. 7).
The C-terminal region (residues 96–140) of S is highly
enriched in negatively charged residues (aspartate and gluta-
mate) (51) and proline residues (52). Long-range interactions of
the C-terminal region (residues 110–130) with the central
hydrophobic NAC region (residues 85–95) (53, 54) are impor-
tant to stabilize the natively unfolded structure (55–57). When
the interaction between the C-terminal and the NAC region is
weakened by low pH, addition of polycations, or changes in
ionic strength, exposure of theNAC region increases, andmore
tightly packed S fibrils are formed (50, 58). Tyrosine residues
located at positions 125, 133, and 136 in the C-terminal region
are crucial to maintain the N- and C-terminal intermolecular
interactions and are related to aggregation (59). In addition to
deletion of charged residues, complete removal of these tyro-
sine residues can result in structural polymorphisms. In the
present study, the C-terminal 20-residue truncated fibrils
showed enhanced seeding activity in vitro, and FLA seededwith
C20 seeds (FLA–C20) exhibited twisted morphologies dis-
tinct from that of the original C20 seeds and others, which
showed straight structure. In our opinion, such twisted mor-
phologies were likely caused by the negatively charged residues,
which exist in FL monomers, but not in C20 seeds. These
Figure 5. Comparison of the stability ofWT andN-terminal truncatedS
fibrils.WT and N-terminally truncated S fibrils were treated with 1% sarko-
syl for 5 min at room temperature. The samples were centrifuged and the
supernatant (S) and the pellet (P) fractions were analyzed by SDS-PAGE. The
image of a gel stained with CBB (upper) and quantification data of S protein
(lower) are shown. Data presented are the means  S.E. percentage of S
protein in the pellet from five independent experiments. *, p  0.05 com-
pared with WTHu.
Figure 6. C-terminal 20-residue truncation of human S also produces
distinctive prion-like properties. A, negative staining TEM imaging of
humanFLSaggregates seededwith FL (left) orC20 (right) seeds. Scale bars,
100 nm. Human FL S aggregates seeded with C20 seeds showed twisted
fibrillar structure. B, aggregation kinetics of human FL S monomers under
quiescent conditions in the absence or presence of 1 mol % human FL S
aggregates seeded with WT or C20 seeds, monitored by measuring ThT
fluorescence. Data are averages of three samples. C, seed-dependent aggre-
gation of S induced by human FL S aggregates seeded with WT or C20
seeds in the cultured cell model. SH-SY5Y cells expressing FLAG-S were
transfected with S monomer (FL Mono), human FL S aggregates seeded
with WT (FLA-WT), or C20 (FLA-C20). Cell extracts were prepared with A68
buffer containing 1% sarkosyl and centrifuged. The supernatant (sup) and the
pellet (ppt) fractions were subjected toWestern blot analysis using anti-pSer-
129 (pSyn#64), anti-FLAG, and anti-tubulin antibodies. D, the intensities of
phosphorylated S in (C) are quantified. ***, p 0.001.
Truncation induces-synuclein fibril polymorphs






















residues might interact with the core region of C20 to form
the twisted morphologies. As a result, C-terminal 20-residue
truncated fibrils induced full-length S polymorphisms.
The N-terminal region (residues 1–60) of human S con-
tains four imperfect 11-residue repeats with a conserved motif
(XKTKEGVXXXX), which interacts with the lipid membrane,
with conformational changes to the-helical structure (26, 56).
Although the N-terminal region directly interacts with the
C-terminal region, but not the central NAC region, (57), N-ter-
minal truncation also increases the ratio of -sheet structure
within S fibrils (56). Recent studies have shown that familial
PD-related mutations located in the N-terminal region influ-
ence the relative stability of the fibrils and their conformational
preferences, rather than the global fibril structures (60, 61).
Truncation of the N-terminal 10 or 30 residues markedly
enhanced cross-seeding activity in mouse brain. Structural
compatibility between the seed and the host protein is impor-
tant for cross-seeding activity in vivo (62).We found thatN-ter-
minal truncation switches the conformational preference of
human S fibrils, making them with structural properties sim-
ilar to those of WTmouse S fibrils, whereas C-terminal trun-
cation does not have such an effect. Furthermore, we also found
that N-terminal 10- or 30-residue truncation reduces confor-
mational stability in a manner that is inversely correlated with
in vivo propagation efficacy. Propagation of prion proteins
depends on the stability of the pathogenic aggregates; less-sta-
ble prions replicate faster than more-stable prions (30). This
would be another reason why these N-terminally truncated
fibrils reduce the species barrier in WT mice. These results
indicate that N-terminal truncation influences the prion-like
seeding activity of S.
As previously reported (62), we also found that propagation
activities in vitro, in cells, and in vivo were not always consis-
tent. In cultured cells, seeding reaction occurs in a more com-
plex environment, such asmolecular crowding, effects of chap-
erones and protein degradation machineries, other proteins
interacting with seeds or monomers, and so on, compared with
the simple reaction buffers used for in vitro assay (63). More-
over, seeds should be taken from outside of cells and escaped
from endosomal vesicles if taken by endosome system in cul-
tured cells. In mice, the cell to cell transmissibility might be
influenced by secretion and uptake of seeds (64). In this study,
we found bothC20 seeds and FLA–C20 seeds hadmarkedly
different seeding activities in vitro versus in cultured cells and
mice. These seeds induced rapid aggregation in vitro, but not in
cells and in mice. Contrary to these seeds, N-terminally trun-
cated seeds such asN30 induced severe pathology in cells and
mice but had reduced seeding activity in vitro. These differ-
ences in propagation characteristics may result from different
susceptibility of fibrils to external factors described above. It
was reported that evenS fibrils that could not propagate effec-
tively inWTmicemight trigger S pathology and neurodegen-
eration when proteolytic systems become less effective with
aging (65) or in the presence of a genetic factor, such as
heterozygous mutation in the lysosomal glucocerebrosidase
gene (GBA1) (66, 67). Therefore, there is a possibility thatC20
seeds induce severe S pathology in aged mice or lysosomal
mutation mice. Consequently, it is important to evaluate the
propagation properties of S fibrils using multiple models.
In summary, our findings indicate that differently truncated
human S can induce various polymorphisms of FL S fibrils
via a seedingmechanism. The properties of N-terminal trunca-
tions of human S imply that the pathogenicity of S involves a
prion-like molecular mechanism. We believe these findings
provide new insights into both the pathogenicity and pheno-
typic diversity of sporadic -synucleinopathies.
Experimental procedures
Antibodies
Antibodies used in the present study were anti–phospho-S
antibodies to pSer-129, including pSyn#64 (3) and EP1536Y
(Abcam), and other anti-S antibodies, including LB509 (a gift
from Dr. Iwatsubo) and D37A6 (Cell Signaling Technology).
Biotin-labeled secondary antibodies were purchased fromVec-
tor Laboratories for use in the avidin–biotin complex method.
Expression and purification of recombinantS proteins
C-terminally truncated S (C10: residues 1–130, C20:
residues 1–120, and C30: residues 1–110) and N-terminally
truncated S (N10: residues 11–140, N20: residues 21–140,
and N30: residues 31–140) were amplified by PCR with the
following primers and subcloned into pRK172 (68, 69): C10,
forward, 5-aggagatatacatatggatgtattcatgaa-3 and reverse, 5-
atcggaattcaagcttttactcataaggcatttcat-3; C20, forward, 5-agg-
agatatacatatggatgtattcatgaa-3 and reverse, 5-atcggaattcaag-
cttttactcataaggcatttcat-3;C30, forward, 5-aggagatatacatatg-
gatgtattcatgaa-3 and reverse, 5-atcggaattcaagcttttactcataagg-
catttcat-3;N10, forward, 5-aggagatatacatatggccaaggagggag-
ttgt-3 and reverse, 5-atcggaattcaagcttttaggcttcaggttcgt-3;
N20, forward, 5-aggagatatacatatgaaaaccaaacagggtgt-3 and
reverse, 5-atcggaattcaagcttttaggcttcaggttcgt-3; N30, for-
ward, 5-aggagatatacatatgggaaagacaaaagaggg-3 and reverse,
5-atcggaattcaagcttttaggcttcaggttcgt-3.
All constructs were verified by DNA sequencing. Recombi-
nant proteins were expressed in E. coli BL21 (DE3) as described
previously (70). Bacterial pellets were sonicated in extraction
buffer A (50mMTris-HCl, pH 7.5, 1 mM EGTA, 1 mMDTT) on
ice. The homogenates were centrifuged at 16,000  g for 15
min, and the supernatants were boiled for 5 min. Then, the
Figure 7. Schematic representation of the effect of truncation on prion-
like properties of S. The N-terminal truncation of human S changes the
structure of the fibrils to a form similar to that ofWTmouseS fibrils. Further-
more, the N-terminally 10- or 30-residue–truncated human S fibrils have
lower conformational stability than WT human S fibrils. As a result, these
fibrils propagate effectively in WT mice. The C-terminally 20-residue–
truncated fibrils showenhanced seedingactivity in vitro, but reduced seeding
activity in cell model and mouse model. There is no direct correlation
between in vitro and in vivo propagation activities.
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supernatants (heat-stable fraction) of 15-min centrifugation at
16,000  g were subjected to anion-exchange (for WT, C10,
C20, N10, 20, and N30) or cation-exchange (for C30)
chromatography on columns (Q Sepharose or SP Sepharose
Fast Flow, respectively; GEHealthcare Japan) equilibrated with
extraction buffer A. The columns were washed with extraction
buffer A and eluted with a 100–500 mM NaCl gradient. The
eluates were concentrated by precipitation with 50% saturated
ammonium sulfate. The pellets were re-suspended in and dia-
lyzed against 30 mM Tris-HCl, pH 7.5. The protein concentra-
tions were determined by reversed phase-HPLC (RP-HPLC),
using an Aquapore RP300 column (71). Purified S samples
were analyzed by 13.5% SDS-PAGE and stained with CBB. Gel
images were recorded with a Gel DocTM EZ Imager (Bio-Rad).
Preparation ofS fibril seeds
S fibrils were prepared as follows. Purified recombinant S
proteins were dissolved in 30 mM Tris-HCl, pH 7.5, containing
150 mM KCl and 0.1% NaN3, to a final concentration of 150 M
protein. The proteins were incubated at 37 °C under linear
shaking at 200 rpm for 7 days. The assembled S was collected
by ultracentrifugation at 135,000  g for 20 min at 25 °C. The
resultant pellets were re-suspended and sonicated in 30 mM,
Tris-HCl, pH 7.5, on ice with an ultrasonic homogenizer (VP-
5S, TAITEC) and ultracentrifuged again. The pellet was re-sus-
pended and sonicated again in 30 mM Tris-HCl, pH 7.5. The
proteins were dissolved in 6 M guanidine hydrochloride and
their concentrations were determined by HPLC as described
above.
Transmission EM
The S fibrils were diluted in 30 mM Tris-HCl pH 7.5 to 15
M, plated on carbon-coated 300-mesh copper grids (Nissin
EM), and stainedwith 2% (v/v) phosphotungstate.Micrographs
were recorded on a JEM-1400Plus electronmicroscope (JEOL).
Thioflavin T-binding assay
The degree of fibrillationwasmeasured in terms of thioflavin
T fluorescence intensity, which is increased when ThT binds to
amyloid-like fibrils. The S proteins (7.5 M) were incubated
with 20MThT in 30mMTris-HCl buffer, pH 7.5, for 30min at
37 °C. Fluorometry was performed using a microplate reader
(Varioskan® Flash, excitation 442 nm, emission 485 nm;
Thermo Scientific) and normalized to the ThT intensity ofWT
S fibrils.
S aggregation assay
Full-length S aggregation experiments were performed
using amicroplate reader (Varioskan® Flash, excitation 442 nm,
emission 485 nm; Thermo Scientific) and monitored by mea-
suring ThT fluorescence in the absence or presence of 1 mol %
sonicated S fibril seeds. All experiments were performed at
37 °C, under quiescent conditions in flat-bottomed 96-well
black plates (Sumitomo Bakelite) sealed with MicroAmp Opti-
cal Adhesive Film (Applied Biosystems) to prevent evaporation.
The reaction mixture consisted of 30 mM Tris-HCl (pH 7.5)
containing 150 mM KCl, 0.1% NaN3, and 20 M ThT. Protein
concentration was 150 M unless otherwise indicated. During
experiments under quiescent conditions, ThT fluorescence
change was read every 6 min.
Proteinase K digestion ofS fibrils
S fibrils (1 mg/ml) in 30 mM Tris-HCl, pH 7.5, were incu-
bated for 30 min at 37 °C in the presence of various concentra-
tions of proteinase K (1, 10, and 100 g/ml; Promega). The
reaction was stopped by boiling the mixture for 10 min. The
samples were analyzed by 15–20% Tris–Tricine–SDS-PAGE;
the gels were stained with CBB (28). Gel images were recorded
with a Gel DocTM EZ Imager (Bio-Rad).
Conformational stability assay ofS fibrils
S fibrils (1 mg/ml) were incubated in 30 mM Tris-HCl, pH
7.5, containing 1% sarkosyl (w/w) for 5 min at room tempera-
ture. After ultracentrifugation at 135,000  g for 20 min at
25 °C, the supernatant was collected as sarkosyl-soluble frac-
tion, and the pellet was re-suspended in 1 SDS-PAGE buffer.
The samples were analyzed by 15% Tris–Tricine–SDS-PAGE;
the gels were stained with CBB (28). Gel images were recorded
with a Gel DocTM EZ Imager (Bio-Rad). The band intensities
were quantified using ImageJ software. Conformational stabil-
ity was determined as the ratio of S in the pellet to total S
(supernatant	 pellet).
Cell culture, transfection of plasmids, and treatment ofS
proteins
Human neuroblastoma SH-SY5Y cells were maintained
at 37 °C in 5% CO2 in DMEM/F12 medium (Sigma-Aldrich)
with 10% fetal calf serum, penicillin-streptomycin-glutamine
(Gibco), and Minimum Eagle’s Medium Nonessential Amino
Acid Solution (Gibco). Cells at a concentration of 1.5  105
cells/ml were cultured to 30–50% confluence in collagen-
coated 6-well plates and transfected with pcDNA3-WTmouse
SorpcDNA3-FLAG-humanSplasmidsusingX-tremeGENE9
(Roche), followed by culture for 16 h. The cells were treated
with final 150 nM S proteins usingMultiFectam (Promega), as
previously described (72).
Immunocytochemistry
SH-SY5Y cells grown on collagen-coated coverslips were
fixed with 4% paraformaldehyde and stained with the indicated
primary antibodies at 1:1,000 dilution. After incubation for 1 h,
cells were washed and treated with secondary antibodies (anti-
rabbit IgG-conjugated Alexa Fluor 568 and anti-mouse IgG-
conjugated Alexa Fluor 488; Invitrogen) and Hoechst 33324
(Sigma-Aldrich) to counterstain nuclear DNA. The cells were
mounted and analyzed using a BZ-X710 (Keyence) and BZ-X
analyzer (Keyence).
Biochemical analysis of cultured cells
After incubation for 2 days, cells were harvested by centrifu-
gation (1,800  g, 5 min) and washed with PBS. The cellular
proteins were extracted with 300 l of buffer A68 (10 mM Tris-
HCl, pH 7.5, 1 mM EGTA, 10% sucrose, 0.8 M NaCl) containing
final 1% sarkosyl (w/w) by sonication. After ultracentrifugation
at 135,000 g for 20min at 25 °C, the supernatantwas collected
as sarkosyl-soluble fraction, and the protein concentration was
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determined by BCA assay. The pellet waswashed oncewith 300
l of buffer A68 containing 1% sarkosyl, and solubilized in 100
l of SDS-sample buffer. Both sarkosyl-soluble and -insoluble
fractions were analyzed by immunoblotting with appropriate
antibodies as indicated (73). The band intensities of insoluble
phospho-S and mouse-S were quantified using ImageJ soft-
ware. The relative amount of precipitate mouse-S was calcu-
lated by insoluble mouse-S divided by insoluble plus soluble
mouse-S. Data are expressed as -fold induction relative to that
in the WT.
S inoculation intomice
Ten-week-old male C57BL/6J mice were purchased from
CLEA Japan, Inc. All experimental protocols were performed
according to the recommendations of the Animal Care andUse
Committee of Tokyo Metropolitan Institute of Medical Sci-




3.5 mm). Inoculation into mouse brain was
performed as described previously (10).
Immunohistochemistry ofmouse brains
Three months after inoculation, mice were deeply anesthe-
tized with pentobarbital injection and sacrificed. The brain was
perfused with 0.1 M PBS, followed by 10% formalin neutral
buffer solution. After fixation, the dissected brain was embed-
ded in paraffin and 5 m–thick serial sections were prepared.
For antigen retrieval, sections were treated with 100% formic
acid (Wako) for 5 min and washed under running tap water,
then brought to a boil in 0.1 M sodium citrate buffer (pH 6.0) for
10 min, followed by cooling for 1 h. Immunohistochemistry
with mAb EP1536Y (1:2,000) directed against S phosphory-
lated at Ser-129 was performed as described previously (10).
Sectionswere counterstainedwith hematoxylin.S pathologies
were analyzedwith a BZ-X710 (Keyence) and quantified using a
BZ-X analyzer (Keyence).
Biochemical analysis of mouse brains
Frozen whole mouse brains were homogenized in 20 vol-
umes of buffer A68 containing final 2% sarkosyl (w/v), and in-
cubated at 37 °C for 30 min. The brain homogenates were
centrifuged at 9,460  g for 20 min at 25 °C, and then the
supernatants were collected and ultracentrifuged at 135,000
g for 20 min at 25 °C. The pellets were washed with 30 mM
Tris-HCl (pH 7.5) and ultracentrifuged as before. The pellet
was once washed with 300 l of buffer A68 containing 1%
sarkosyl, and solubilized in 100 l of SDS–sample buffer. Both
sarkosyl-soluble and -insoluble fractions were analyzed by
Western blotting with appropriate antibodies as indicated (10).
The band intensities of insoluble phospho-S and mouse-S
were quantified using ImageJ software. The relative amount of
precipitate mouse-S was calculated by insoluble mouse-S
divided by insoluble plus solublemouse-S. Data are expressed
as -fold induction relative to that in the WT.
Statistical analysis
Graphs were created, and statistics were calculated in Prism
ver. 5 (GraphPad Software, San Diego, CA). Multiple group
comparisons were made by one-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test. Data are pre-
sented as mean S.E. unless otherwise noted. Significance was
determined at *, p 0.05, **, p 0.01, and ***, p 0.001.
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